Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Helena Chang, M.D.
Helena Chang, M.D.


Cancer/Surgical Oncology
Surgery General

General Information:

Chinese, English


Director, Revlon/UCLA Breast Center
Professor, Department of Surgery
Physician, Department of Surgery, Surgical Oncology
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center


Surgery/Oncology, Memorial Sloan-Kettering Cancer Center, 1986 - 1988
Surgery, Episcopal Hospital, 1981 - 1986
Medical Degree:
M.D., Temple University School of Medicine, 1981

Contact Information:

(310) 794-5624
(310) 794-7788 Surgery patient appointments
(310) 206-6909 Surgical Oncology information and referral
(310) 206-6931 Surgical Oncology follow-up appointments
(310) 825-2644 Surgical Oncology referring physician
(310) 825-2144 Revlon/UCLA Breast Center patient referral coordinator

Practice Information:

Clinical Interest(s):

Scientific Interest(s):

Dr. Helena Chang's long-term research interest is in the development of immunotherapy in treating adult ductal epithelial cancer. Chang has developed several recombinant live vaccines that actively secrete a tumor antigen and human cytokines. The role of these vaccines in human cancer treatment and prevention is being investigated. The biological activity of the targeted tumor antigen (MUC-1 peptide) and its involvement in cancer invasion and metastases is being characterized by her research team. She is also working closely with clinician-scientists and basic researchers in studies that characterize breast cancer behavior and develop molecular classifications for locally advanced breast cancer.

Selected Cancer-Related Publications:

He J, Whelan SA, Lu M, Shen D, Chung DU, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response. Int J Proteomics. 2011 Oct 24;2011:896476.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010 Sep 15;116(18):4227-37.

Lu M, Whelan SA, He J, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer. Clin Proteomics. 2010 Sep;6(3):93-103.

He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, Faull KF, Chang HR. Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol. 2009 Oct;35(4):683-92.

Whelan SA, Lu M, He J, Yan W, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J Proteome Res. 2009 Aug;8(8):4151-60.